Increased risk of adefovir resistance in patients with lamivudine‐resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy
Yoon‐Seon Lee, Dong Jin Suh, Young‐Suk Lim, Suk Won Jung, Kang Mo Kim, Han Chu Lee, Young‐Hwa Chung, Yung Sang Lee, Wangdon Yoo, Soo‐Ok Kim – 25 May 2006 – Although adefovir dipivoxil (ADV) has a unique profile of delayed and infrequent resistance in treatment‐naïve chronic hepatitis B patients, the association of ADV resistance with previous lamivudine (LAM) resistance is not well understood. We compared the emergence of the ADV‐resistant mutations rtA181V/T and rtN236T between LAM‐resistant patients and treatment‐naïve patients at 48 weeks of ADV monotherapy.